A Study Of Free Tacrolimus Level In Solid Organ Transplant Recipients

Overview

About this study

The purpose of this study it to characterize the effects of altered protein physiologic states on EDTA plasma free and EDTA whole blood tacrolimus concentrations.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Taking enteral tacrolimus immediate release capsules or granules

  • Adult solid organ transplant recipient (age ≥ 18)

  • Pregnant, on ECMO, or malnourished with ICD-10 code E.43 “Unspecified severe protein-calorie malnutrition”

 

Exclusion Criteria:

  • Extended release tacrolimus

  • Switched from tacrolimus to another immunosuppressant

  • Sublingual tacrolimus

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/26/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Paul Jannetto, Ph.D.

Contact us for the latest status

Contact information:

DLMP Research and Innovation Office

(507) 284-9080

DLMPRIO@mayo.edu

More information

Publications

Publications are currently not available